Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 157.66 |
---|---|
High | 157.66 |
Low | 157.66 |
Bid | 154.11 |
Offer | 155.25 |
Previous close | 98.31 |
Average volume | -- |
---|---|
Shares outstanding | 18.90m |
Free float | 18.54m |
P/E (TTM) | 49.12 |
Market cap | 2.25bn USD |
EPS (TTM) | 2.43 USD |
Data delayed at least 15 minutes, as of Mar 15 2021.
More ▼
Press releases
- Ligand to Present at Stifel 2024 Healthcare Conference
- Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
- Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
- Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
More ▼